CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia

British Journal of Haematology
Bas KerstenGerrit Jan Schuurhuis

Abstract

Chemotherapy resistant leukaemic stem cells (LSC) are thought to be responsible for relapses after therapy in acute myeloid leukaemia (AML). Flow cytometry can discriminate CD34(+) CD38(-) LSC and normal haematopoietic stem cells (HSC) by using aberrant expression of markers and scatter properties. However, not all LSC can be identified using currently available markers, so new markers are needed. CD45RA is expressed on leukaemic cells in the majority of AML patients. We investigated the potency of CD45RA to specifically identify LSC and HSC and improve LSC quantification. Compared to our best other markers (CLL-1, also termed CLEC12A, CD33 and CD123), CD45RA was the most reliable marker. Patients with high percentages (>90%) of CD45RA on CD34(+) CD38(-) LSC have 1·69-fold higher scatter values compared to HSC (P < 0·001), indicating a more mature CD34(+) CD38(-) phenotype. Patients with low (<10%) or intermediate (10-90%) CD45RA expression on LSC showed no significant differences to HSC (1·12- and 1·15-fold higher, P = 0·31 and P = 0·44, respectively). CD45RA-positive LSC tended to represent more favourable cytogenetic/molecular markers. In conclusion, CD45RA contributes to more accurate LSC detection and is recommended for in...Continue Reading

References

Aug 20, 1987·The New England Journal of Medicine·P J FialkowR Veith
Sep 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emmanuelle PasseguéIrving L Weissman
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna van RhenenGerrit Jan Schuurhuis
Oct 24, 2007·Nature Biotechnology·Fumihiko IshikawaLeonard D Shultz
Mar 29, 2008·Cell Stem Cell·Ravindra MajetiIrving L Weissman
Dec 10, 2008·Blood·John E Dick
Jan 11, 2011·Blood Reviews·Michael W Becker, Craig T Jordan
Aug 31, 2012·Science Translational Medicine·Max JanRavindra Majeti
Mar 26, 2013·American Journal of Hematology·Elihu H Estey
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monique TerwijnGerrit J Schuurhuis
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie D FreemanAlan K Burnett
Oct 24, 2013·Cytometry. Part B, Clinical Cytometry·W ZeijlemakerG J Schuurhuis
Jun 25, 2015·British Journal of Haematology·Wendelien ZeijlemakerGerrit J Schuurhuis

❮ Previous
Next ❯

Citations

Mar 10, 2017·Expert Opinion on Drug Discovery·Gillian A Horne, Mhairi Copland
Mar 31, 2017·International Journal of Hematology·Diana HanekampGerrit Jan Schuurhuis
Jul 3, 2017·Experimental Hematology·Alison A LaingKaren Keeshan
Nov 26, 2019·Current Protocols in Cytometry·Wendelien ZeijlemakerGerrit Jan Schuurhuis
Aug 31, 2017·Journal of Hematology & Oncology·Mingxue FanLei Yu
Sep 1, 2019·International Journal of Molecular Sciences·Peter ValentDominik Wolf
Oct 24, 2019·Molecular Biology Reports·Shima Moradi-KalbolandiLeila Farahmand
Mar 9, 2018·BioMed Research International·Xiangchou YangHong Wang
Dec 29, 2020·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Marianne A PetersenCarina A Rosenberg
Dec 17, 2020·Cancers·Marlon ArnoneClaudia Lengerke
Apr 28, 2020·Hematology/oncology Clinics of North America·Mayumi Sugita, Monica L Guzman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.